Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P‐glycoprotein

Identifieur interne : 002243 ( Main/Merge ); précédent : 002242; suivant : 002244

Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P‐glycoprotein

Auteurs : Lawrence D. Mayer [Canada] ; Kye-Taek Lim [Corée du Sud] ; Daria Hartley

Source :

RBID : ISTEX:31C4FAD3FB5DF20345AF10144AF5E214682C8EC4

Abstract

Although the ability of chemosensitizers to modulate P‐glycoprotein (PGP)‐based multidrug resistance (MDR) has been extensively studied, relatively little is known about the cellular pharmacology of the PGP inhibitors themselves in MDR cells. The studies described here have correlated the in vitro accumulation and retention properties of verapamil (VRP) in murine P388 (sensitive) and P388/ADR (MDR) cells with doxorubicin (DOX) uptake and cytotoxicity modulation characteristics in order to better understand VRP–tumor cell interactions that give rise to MDR modulation. VRP is rapidly taken up by DOX‐sensitive and ‐resistant P388 cells where greater than 50% maximal VRP uptake occurs within 10 min of initial exposure at 37°C. Whereas chemosensitization and DOX uptake in P388/ADR cells increase with increasing VRP concentration until a plateau is achieved at approximately 5 μM VRP, cellular modulator levels increase proportionally with increasing VPR concentrations beyond 20 μM. Subsequent to removal of noncell‐associated modulator, VRP levels in both sensitive and resistant cells rapidly fall below 10% of those obtained at uptake equilibrium. However, a residual amount of VRP remains associated with the cells for extended time periods after the cells are washed. Pulse exposures of P388/ADR cells to high concentrations of VRP (50–100 μM) are capable of providing extended cell‐associated VRP levels comparable to those obtained with continuous exposure at biologically active VRP concentrations (1–3 μM) and this leads to chemosensitization. These results are consistent with the existence of high‐ and low‐affinity intracellular VRP pools in P388 MDR cells, both of which can contribute to the reversal of drug resistance. It is suggested that these properties should be taken into consideration during the design and evaluation of preclinical in vivo MDR models where pulsed exposure to high concentrations of resistance modulators often occurs. Special attention must be given to whether such high concentration pulses are desirable and/or achievable in relevant clinical settings.

Url:
DOI: 10.1046/j.1359-4117.2002.1009x.x

Links toward previous steps (curation, corpus...)


Links to Exploration step

ISTEX:31C4FAD3FB5DF20345AF10144AF5E214682C8EC4

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P‐glycoprotein</title>
<author>
<name sortKey="Mayer, Lawrence D" sort="Mayer, Lawrence D" uniqKey="Mayer L" first="Lawrence D." last="Mayer">Lawrence D. Mayer</name>
</author>
<author>
<name sortKey="Lim, Kye Aek" sort="Lim, Kye Aek" uniqKey="Lim K" first="Kye-Taek" last="Lim">Kye-Taek Lim</name>
</author>
<author>
<name sortKey="Hartley, Daria" sort="Hartley, Daria" uniqKey="Hartley D" first="Daria" last="Hartley">Daria Hartley</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:31C4FAD3FB5DF20345AF10144AF5E214682C8EC4</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1046/j.1359-4117.2002.1009x.x</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-PJCNFFZ1-X/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001A25</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001A25</idno>
<idno type="wicri:Area/Istex/Curation">001A25</idno>
<idno type="wicri:Area/Istex/Checkpoint">001048</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001048</idno>
<idno type="wicri:doubleKey">1359-4117:2002:Mayer L:identification:of:two</idno>
<idno type="wicri:Area/Main/Merge">002243</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main">Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P‐glycoprotein</title>
<author>
<name sortKey="Mayer, Lawrence D" sort="Mayer, Lawrence D" uniqKey="Mayer L" first="Lawrence D." last="Mayer">Lawrence D. Mayer</name>
<affiliation></affiliation>
<affiliation></affiliation>
<affiliation wicri:level="1">
<country>Canada</country>
<wicri:regionArea>Correspondence address: L.D. Mayer, Department of Advanced Therapeutics, The British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC</wicri:regionArea>
<wicri:noRegion>BC</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Lim, Kye Aek" sort="Lim, Kye Aek" uniqKey="Lim K" first="Kye-Taek" last="Lim">Kye-Taek Lim</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of Protein Engineering, Institute of Biotechnology, Chonnam National University, Kwangju City, Yongbong Dong 300</wicri:regionArea>
<wicri:noRegion>Yongbong Dong 300</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Hartley, Daria" sort="Hartley, Daria" uniqKey="Hartley D" first="Daria" last="Hartley">Daria Hartley</name>
<affiliation>
<wicri:noCountry code="subField"></wicri:noCountry>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">Journal of Experimental Therapeutics and Oncology</title>
<title level="j" type="alt">JOURNAL OF EXPERIMENTAL THERAPEUTICS AND ONCOLOGY</title>
<idno type="ISSN">1359-4117</idno>
<idno type="eISSN">1533-869X</idno>
<imprint>
<biblScope unit="vol">2</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="107">107</biblScope>
<biblScope unit="page" to="120">120</biblScope>
<biblScope unit="page-count">14</biblScope>
<publisher>Blackwell Science Inc</publisher>
<pubPlace>Boston, MA, USA</pubPlace>
<date type="published" when="2002-03">2002-03</date>
</imprint>
<idno type="ISSN">1359-4117</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">1359-4117</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Although the ability of chemosensitizers to modulate P‐glycoprotein (PGP)‐based multidrug resistance (MDR) has been extensively studied, relatively little is known about the cellular pharmacology of the PGP inhibitors themselves in MDR cells. The studies described here have correlated the in vitro accumulation and retention properties of verapamil (VRP) in murine P388 (sensitive) and P388/ADR (MDR) cells with doxorubicin (DOX) uptake and cytotoxicity modulation characteristics in order to better understand VRP–tumor cell interactions that give rise to MDR modulation. VRP is rapidly taken up by DOX‐sensitive and ‐resistant P388 cells where greater than 50% maximal VRP uptake occurs within 10 min of initial exposure at 37°C. Whereas chemosensitization and DOX uptake in P388/ADR cells increase with increasing VRP concentration until a plateau is achieved at approximately 5 μM VRP, cellular modulator levels increase proportionally with increasing VPR concentrations beyond 20 μM. Subsequent to removal of noncell‐associated modulator, VRP levels in both sensitive and resistant cells rapidly fall below 10% of those obtained at uptake equilibrium. However, a residual amount of VRP remains associated with the cells for extended time periods after the cells are washed. Pulse exposures of P388/ADR cells to high concentrations of VRP (50–100 μM) are capable of providing extended cell‐associated VRP levels comparable to those obtained with continuous exposure at biologically active VRP concentrations (1–3 μM) and this leads to chemosensitization. These results are consistent with the existence of high‐ and low‐affinity intracellular VRP pools in P388 MDR cells, both of which can contribute to the reversal of drug resistance. It is suggested that these properties should be taken into consideration during the design and evaluation of preclinical in vivo MDR models where pulsed exposure to high concentrations of resistance modulators often occurs. Special attention must be given to whether such high concentration pulses are desirable and/or achievable in relevant clinical settings.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002243 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002243 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     ISTEX:31C4FAD3FB5DF20345AF10144AF5E214682C8EC4
   |texte=   Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P‐glycoprotein
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021